Eicosanoids and Hypertension Pharmacology
Eicosanoids and Hypertension Pharmacology is a research topic within Biochemistry. Science Explorer counts 36k research works in it since 1950. 19.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the metabolism, function, and therapeutic implications of arachidonic acid derivatives, particularly epoxyeicosatrienoic acids (EETs), cytochrome P450 enzymes, and soluble epoxide hydrolase. The research covers their roles in cardiovascular function, inflammation, hypertension, and potential as therapeutic targets.
- Arachidonic Acid
- Epoxyeicosatrienoic Acids
- Cytochrome P450
- Soluble Epoxide Hydrolase
- Cardiovascular Function
- Inflammation
- Hypertension
- Eicosanoids
- Metabolism
- Therapeutic Target
- Research works
- 36k fractional, since 1950
- In the world top 10%
- 6.8k per year above
- Top-10% rate
- 19.0% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- -8% the tick is no change
Which countries lead Eicosanoids and Hypertension Pharmacology research?
By volume, the United States and China publish the most (655 and 648 works in 2022–2025).
By volume, 2022–2025
- 1 United States 655 works
- 2 China 648 works
- 3 Russia 128 works
- 4 Japan 127 works
- 5 India 126 works
- 6 Germany 100 works
- 7 Italy 78 works
- 8 United Kingdom 71 works
- 9 South Korea 69 works
- 10 Spain 58 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Eicosanoids and Hypertension Pharmacology research?
By volume in 2022–2025, University of California, Davis publishes the most Eicosanoids and Hypertension Pharmacology research, followed by University of Alberta and Volgograd State Technical University.
By volume, 2022–2025
- 1 University of California, DavisUnited States 22 works
- 2 University of AlbertaCanada 12 works
- 3 Volgograd State Technical UniversityRussia 11 works
- 4 University of North Carolina at Chapel HillUnited States 11 works
- 5 University of MichiganUnited States 9 works
- 6 Harvard UniversityUnited States 9 works
- 7 Michigan State UniversityUnited States 9 works
- 8 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 8 works
- 9 University of PittsburghUnited States 8 works
- 10 University of ArizonaUnited States 8 works
Who are the leading researchers in Eicosanoids and Hypertension Pharmacology?
The most-cited researchers publishing on Eicosanoids and Hypertension Pharmacology include Giuseppe Remuzzi, Walter C. Willett and Dariush Mozaffarian.
- 1 Giuseppe Remuzzi Italy 8.1k citations
- 2 Walter C. Willett United States 6.8k citations
- 3 Dariush Mozaffarian United States 5.2k citations
- 4 Deepak L. Bhatt United States 4.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Eicosanoids and Hypertension Pharmacology research done?
The largest centres of Eicosanoids and Hypertension Pharmacology research in 2022–2025 are Beijing (China), Shanghai (China), Moscow (Russia) and Tokyo (Japan). Among places with at least 20 works in it, it is an unusually large share of all research in Davis.
Largest cities, 2022–2025
Where it is the local speciality
- DavisUS · 22.4 works11×
Location quotient: how much more of its research is in Eicosanoids and Hypertension Pharmacology than the world average.
Where is the best place to study Eicosanoids and Hypertension Pharmacology?
Among universities, judged by research, University of California, Davis, Harvard University and University of Alberta score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | University of California, DavisUnited States | 64.3 | 12.2% | 10.8× | 22 | +1.1% |
| 2 | Harvard UniversityUnited States | 41.8 | 32.0% | 2.5× | 9 | -26.1% |
| 3 | University of AlbertaCanada | 34.2 | 7.8% | 5.1× | 12 | -22.3% |
| 4 | Volgograd State Technical UniversityRussia | 32.6 | 0.0% | 54.8× | 11 | -5.6% |
| 5 | University of MichiganUnited States | 31.6 | 16.2% | 2.5× | 9 | +74.0% |
| 6 | University of North Carolina at Chapel HillUnited States | 30.9 | 9.3% | 2.3× | 11 | +157.6% |
| 7 | Michigan State UniversityUnited States | 30.0 | 18.0% | 4.3× | 8 | -23.4% |
| 8 | University of PittsburghUnited States | 29.4 | 17.6% | 4.0× | 8 | -1.2% |
| 9 | University of ArizonaUnited States | 23.5 | 9.5% | 4.6× | 8 | -0.0% |
| 10 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 18.0 | 11.9% | 3.2× | 8 | -23.2% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Eicosanoids and Hypertension Pharmacology research growing?
Output in 2018–2022 was 8% lower than in 2013–2017, peaking in 2008.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.